Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV− HNSCC

Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 has been used for the treatment of head and neck squamous cell carcinoma (HNSCC). However, the overall response rate to ICB therapy for HNSCC remains less than 20%. It has recently been reported that the appearance of tertiary lymphoid structures...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dental research 2023-06, Vol.102 (6), p.678-688
Hauptverfasser:	Li, H., Zhu, S.-W., Zhou, J.-J., Chen, D.-R., Liu, J., Wu, Z.-Z., Wang, W.-Y., Zhang, M.-J., Sun, Z.-J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Animals Carcinoma, Squamous Cell - therapy CD20 antigen CD4 antigen CD8 antigen CD8-Positive T-Lymphocytes Dendritic cells Genomes Head & neck cancer Head and neck carcinoma Head and Neck Neoplasms - therapy Human papillomavirus Humans Immune checkpoint inhibitors Immunotherapy Immunotherapy - methods Lymphocytes Lymphocytes B Lymphocytes T Medical prognosis Mice Papillomavirus Infections - therapy PD-1 protein PD-L1 protein Prognosis Programmed Cell Death 1 Receptor - therapeutic use Response rates Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - therapy Tertiary Lymphoid Structures Tumor Microenvironment Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!